Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Nitto Denko Avecia Expands Specialized Pharmaceutical Production in Milford, Massachusetts

07/14/2017
Nitto Denko Avecia Inc. will open of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, Massachusetts.

The firm is a recognized leader in manufacturing and development of oligonucleotide therapeutics. Oligonucleotides are DNA or RNA molecules, called oligomers, that have a wide range of applications in genetic testing, research, and forensics.

The expansion will add 20,000 square feet of manufacturing and office space at Avecia's Milford site and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol. The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MA the largest oligonucleotide manufacturing site in the world.

According to Avecia's President Detlef Rethage, "This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned. "Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics," said Rethage.

Avecia has added more than 120 MA jobs in the last 12 months in Milford and currently has more than 50 open positions at its four locations in Massachusetts, Ohio, and California. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering.

Nitto Denko Avecia Inc. operates facilities located in Milford and Marlboro, Massachusetts and Cincinnati, Ohio offering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg + post commercial launch.

Exclusive Research